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Migraine is a common neurological disorder characterized by recurrent headache
episodes that accompany sensory-motor disturbances, such as higher sensitivity to
touch and light, extremity heaviness or weakness, and speech or language disabilities.
Worldwide, migraine is one of the top 10 causes of disability and hence poses a huge
economic burden to society. On average, migraine occurs in 12% of population but
its occurrence is sexually dimorphic, as it is two to three times more prevalent in
women than in men. This female to male ratio of migraine prevalence is age- and sex
hormone-dependent. Advancements in understanding migraine pathogenesis have also
revealed an association with both genetics and epigenetics. The severity of migraine, in
terms of its attack duration, headache intensity, frequency, and occurrence of migraine-
associated symptoms, has generally been reported to be greater in women. Sex
differences in migraine disability and comorbidities, such as psychiatric disorders, have
also been noted in some population-based studies. However, research on sex-related
differences in response to migraine treatments is relatively scarce. Although a general
observation is that women consume more medication than men for migraine treatment,
strategies for the use of abortive and preventive medications for migraine are generally
similar in both sexes. This narrative review summarizes available findings on sexually
distinct responses to abortive and prophylactic pharmacotherapy of migraine. Basic
experimental data and clinical findings will be presented, and potential mechanisms
underlying sex-based responses will be discussed to highlight the importance and value
of sex-based treatment in migraine research and practice.
Keywords: migraine, headache, female, male, sex, prophylactic, acute, abortive
NARRATIVE REVIEW
This narrative review provides an overview of the current knowledge on sex-specific
pharmacotherapy for migraine with the idea of summarizing available information in the field
and highlighting pending questions that are yet to be considered in future studies. As pointed out
carefully by Peterlin et al. (2011), recognition of factors influencing sex-based responses in migraine
is important; however, it needs to be followed with utilization of findings in a meaningful manner
both in migraine research and practice to advance treatment and prevention of this disorder.
Migraines are moderate to severe primary headaches that may be preceded by aura, and
accompanied by nausea and photophobia. The prevalence of migraine is similar in pre-pubescent
Frontiers in Neuroscience | www.frontiersin.org 1 March 2020 | Volume 14 | Article 222
fnins-14-00222 March 19, 2020 Time: 17:14 # 2
Gazerani and Cairns Toward Sex-Specific Migraine Therapy
boys and girls, but beginning at puberty, young women suffer
twice as commonly from migraine as young men (Finocchi and
Strada, 2014; Wilcox et al., 2018). In women, the peak prevalence
of migraine occurs around age 30–40 years, after which it declines
(Finocchi and Strada, 2014). Women also suffer more attacks per
month than young men of the same age, and about twice as many
will progress to a chronic form of the headache (>15 headaches
per month) (Wilcox et al., 2018). Women have longer, more
intense headaches and a greater overall sensory hypersensitivity,
particularly facial cutaneous allodynia (Finocchi and Strada,
2014; Wilcox et al., 2018).
It is thought that sensitization of dural afferent fibers causes
the head pain symptoms typically reported by migraine sufferers
(Levy et al., 2018). Neurogenic inflammation, which results
from a localized release of neurotransmitters, such as serotonin,
histamine, and glutamate as well as neuropeptides, such as
calcitonin gene-related peptide (CGRP) and substance P, may
underlie this sensitization. These substances produce alterations
in cerebral vascular tone, promote plasma protein extravasation,
and decrease the activation threshold for dural afferent fibers.
There is still controversy over how the process of neurogenic
inflammation is triggered. Given the diversity of migraine
headache triggers in patients, it is likely that both central and
peripheral mechanisms are involved.
Estrogen appears to play a role in sex differences. Dural
application of “inflammatory soup” (IS) has been used to
examine behavioral or electrophysiological changes associated
with meningeal inflammation. Females show an increased
sensitivity to IS application compared with males (Stucky et al.,
2011). Elevated estrogen levels increase the response of dural
afferent fibers and brainstem trigeminal sensory neurons (Bolay
et al., 2011; Scheff and Gold, 2011; Finocchi and Strada, 2014;
Pavlovic et al., 2017). Both estrogen receptors (ERs), ERα and
ERβ, are widely expressed by trigeminal ganglion neurons (Wang
et al., 2012; Pavlovic et al., 2017). Estrogen can exert a direct
sensitizing effect on trigeminal afferent fibers specifically through
ERα (Rowan et al., 2014). Women who suffer migraine with aura
have elevated plasma estrogen levels compared with women who
have migraine without aura (Nagel-Leiby et al., 1990). Migraine
without aura is often reduced during pregnancy, whereas
migraine with aura is often worsened by oral contraceptive
use (Bolay et al., 2011). It is hypothesized that the rate of
change of estrogen levels is a trigger for headaches, for example,
women with migraine appear to have a faster decline in estrogen
prior to headache than healthy women (Macgregor et al., 2006;
Pavlovic et al., 2017). Men with migraine have also been reported
to have higher plasma levels of estrogen than men without
migraine (Van Oosterhout et al., 2018). Other hormones, such as
testosterone, progesterone, and prolactin, as well as genetic and
epigenetic factors, may contribute to these sex-related differences
in migraine (Gazerani and Vinterhøj, 2016; Delaruelle et al., 2018;
Gazerani, 2019).
Sex-related responses in migraine are not limited to
biological factors, such as sex hormones. Genetic and epigenetic
factors, environmental stressors, psychosocial factors, and coping
strategies in response to stress and pain perception are among
other contributing factors. The magnitude and influence of
psychosocial factors (including stress, anxiety, and irritability)
have been found greater in female migrainures than in males
(Lebedeva et al., 2017). Attempts have provided evidence
on psychosocial considerations in migraine. Psychological
interventions have also been proposed to offer beneficial value to
pharmacotherapy (Sullivan et al., 2016). Readers are referred to
other reviews in the field (e.g., Raggi et al., 2012). Migraine is also
co-morbid with several disorders, such as psychiatric disorders
and comorbidity not only influences the course and severity of
migraine but also responsiveness to treatment and prevention.
Sex-Related Differences in Response to
Pharmacotherapy
The pharmacotherapy of migraine involves two strategies:
treatment of the acute headache with drugs intended to reduce
or eliminate headache pain, termed abortives, and use of drugs
intended to prevent migraine headaches, known as prophylactics.
The response to abortive agents is usually assessed at 2 and 24 h
after drug administration. It is often described in the literature as
the percentage of sufferers who are “headache free” at these two
time points, however, studies also report the number of subjects
who have a clinically meaningful reduction in their headache
pain, which varies from a 30 to 50% decrease in headache pain
intensity, depending on the authors. The efficacy of prophylactic
therapy is commonly assessed by a reduction in the number of
days with headache, or alternatively the number of headaches.
Many studies consider that a 50% reduction in headache days
is a clinically meaningful measure of the efficacy of prophylactic
drugs. As most studies rely on sufferer-reported data, there is
significant interest in developing biomarkers to more objectively
monitor the efficacy of migraine pharmacotherapy; however, a
reliable, commonly accepted biomarker for migraine treatment
has not been identified (Gazerani, 2019). One promising
approach is to combine genetic and brain imaging markers to
identify the optimal migraine therapy (Nyholt et al., 2017).
Abortive Treatment of Migraine
Abortive agents can be classified by their pharmacological
action into the following groups: Ergot alkaloids, triptans, non-
steroidal anti-inflammatory drugs (NSAIDs) and paracetamol,
opioids, and other miscellaneous agents. Studies rarely look
at sex-related differences in the efficacy of abortives (van
Casteren et al., 2019). This omission is perhaps because of
the predominance of migraine in women, which results in far
fewer men being included in drug efficacy studies for this
condition (Vetvik and Macgregor, 2017). Whereas women tend
to use prescription medication (e.g., triptans and ergotamine) for
abortive medication, men are more likely to use over the counter
medications, including NSAIDs, in particular acetylsalicylic acid
(ASA), ibuprofen, naproxen, and diclofenac (Buse et al., 2013;
Vetvik and Macgregor, 2017). Interestingly, men are less likely
to report an adequate response to therapy than women at both
2 and 24 h (Lipton et al., 2016a,b). In contrast, female sex is a
significant predictor of recurrence (Dodick et al., 2008). Women
may also have a higher relapse rate of migraine headache pain
than men, but not all studies support this (Dodick et al., 2008).
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Triptans
Triptans were developed to more specifically target 5-HT1B/D
receptor mechanisms recognized to be key to the antimigraine
mechanism of ergot alkaloids. They are vasoconstrictive, through
an effect on serotonin (5-HT)1B receptors, and suppress release
of neuropeptides through 5-HT1D receptors, which are located
on cerebrovascular endothelium and dural afferent fibers,
respectively. These actions reduce neurogenic inflammation and
dural afferent sensitization. Lasmiditan is a newly approved
agonist of the 5-HT1F receptor. Activation of this receptor
decreases neuronal excitability in the migraine headache pain
pathway presumably by a central effect, as this drug does not
appear to exert the typical peripheral effects of triptans, such as
vasoconstriction (Goadsby and Classey, 2003).
In animals, 5-HT levels in the dorsal raphe nucleus are
modulated estrogen, through a combination of estrogen-related
increased tryptophan hydroxylase levels, and decreased reuptake
(Gupta et al., 2011; Aggarwal et al., 2012). As estrogen levels drop,
5-HT levels in the brain decline. Further, estrogen has been found
to attenuate 5-HT induced vasoconstriction (Gupta et al., 2011).
In ovariectomized female rats, the expression of 5HT1B receptors
in the trigeminal ganglion is reduced by about one-third
(Aggarwal et al., 2012). Estrogen treatment of ovariectomized
female rats restores the level of 5HT1B receptor expression
to that seen in normally cycling rats (Aggarwal et al., 2012).
Injection of sumatriptan is known to induce localized mechanical
sensitivity, in a sexually dimorphic manner, with female rats
showing sensitivity at lower sumatriptan concentrations than
males (Araldi et al., 2017). This effect appears to be mediated
by estrogen, as gonadectomy attenuates and estrogen treatment
enhances it (Araldi et al., 2017). Somewhat surprisingly, in female
rats, sumatriptan induced mechanical sensitivity is mediated
through 5-HT1D receptors, whereas in male rats, it is mediated
through 5-HT1B receptors.
It has been reported that oral administration of frovatriptan
2.5 mg produces peak and area under the curve plasma
concentrations that are about twice as high in women as in
men due to an apparent lower bioavailability in men (Jhee
et al., 2001; Elkind et al., 2004; Negro et al., 2011). Frovatriptan,
perhaps due to its long half-life, has a lower rate of headache
recurrence than other triptans at 24 h post-administration, but
also suffers from a lowered headache relief rating at 2 h (Jhee et al.,
2001; Negro et al., 2011). Importantly, naratriptan, rizatriptan,
and zolmitriptan also show similar, although less dramatic, sex-
related differences in peak and area under the curve plasma
concentrations (Ferrari et al., 2011). It is not clear what, if any,
relationship exists between the efficacy of these agents in migraine
and the plasma concentration achieved (Ferrari et al., 2011;
Vetvik and Macgregor, 2017). However, in comparison trials of
frovatriptan versus rizatriptan, zolmitriptan, or almotriptan, all
produced relatively similar efficacy to ameliorate or eliminate
migraine headache, which was not different when men and
women were compared (Franconi et al., 2014). A recent meta-
analysis did, however, find an increased risk for women to have
headache reoccurrence 24 and 48 h after triptan treatment,
and concluded that this was not explained by a different initial
response to these abortive drugs (van Casteren et al., 2019).
This same meta-analysis found that women also have a higher
risk of adverse events than men when treated with triptans (van
Casteren et al., 2019). Most studies of triptans for migraine have a
much smaller number of men than of women and thus response
efficacy stratified by sex is not often reported (Vetvik and
Macgregor, 2017). This was also the case in the study of Franconi
et al. (2014) where the female to male ratio was more than 4:1, and
thus it is unclear if this confound prevented the identification of
sex-related differences in triptan efficacy (Franconi et al., 2014).
Thus, one cannot exclude the possibility that low numbers of
men in these studies precluded an identification of an actual
sex-related difference in efficacy.
NSAIDs
Non-steroidal anti-inflammatory drugs act by inhibition of
the enzyme cyclooxygenase, which converts arachidonic acid
to prostaglandins, of which prostaglandin E, F2α, and I
(prostacyclin) are thought to contribute to headache pain, in
part by sensitizing afferent fibers and altering the excitability
of trigeminovascular neurons (Dong et al., 2009). Paracetamol
is a non-specific mild analgesic used by some migraineurs. Its
mechanism of action with regard to migraine is uncertain. In a
human experimental pain study that examined the effectiveness
of ibuprofen 800 mg on electrically evoked ear lobe pain tolerance
in healthy men and women, only men showed a significant
analgesic response (Walker and Carmody, 1998). The only
sex-related difference in pharmacokinetic (PK) parameters was
the weight-adjusted volume of distribution, which was twice
as high in women. No relationship between plasma ibuprofen
concentration and analgesia in men was identified, suggesting
that the slightly higher concentrations of ibuprofen found in men
were not likely the explanation for this sex-related difference.
Subsequent research by the same group found that expectation
of analgesia in men was the likely reason for the difference in
ibuprofen efficacy in this model (Butcher and Carmody, 2012).
The absorption of ketoprofen is more rapid in men than in
women, with men achieving higher maximum concentrations
in the plasma (Lorier et al., 2016; Magallanes et al., 2016);
however, this NSAID is not as commonly used for acute migraine
treatment. Not all NSAIDs show a sex-related difference in their
PK. Diclofenac potassium oral solution, which is used as an
abortive for migraine headache, has not been shown to have a
different disposition in men compared with women (Chen et al.,
2015). Ketorolac, an NSAID, which is available in injectable form,
has been shown to be effective as a migraine abortive agent (Rao
et al., 2016). There is no clinical evidence that ketorolac has a sex-
related difference in its efficacy (Friedman et al., 2015). However,
in an animal model of masticatory muscle pain, peripheral
application of ketorolac was found to exert a significantly greater
effect in female rats (Cairns et al., 2012). The relevance of this
finding to the actions of ketorolac as a migraine abortive is
uncertain, but at least theoretically, this suggests that certain
NSAIDs may work better in one sex than in another.
Orally ingested ASA is absorbed more quickly in women
than in men, but is also hydrolyzed (de-acetylated) and cleared
more rapidly from the plasma of women, which may explain
a decreased efficacy of ASA as an antithrombolytic in female
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migraineurs (Buchanan et al., 1983; Jesurum et al., 2012).
However, in a retrospective study of 61 migraine patients,
no sex-related difference in the efficacy of ASA to ameliorate
migraine headache was found, although the authors speculated
that plasma concentrations of intact ASA might be predictive of
response (Ross-Lee et al., 1983). A study of a combination of
paracetamol, ASA, and caffeine (Excedrin) in men and women
migraineurs showed a trend toward higher headache pain relief
as the percentage of men in the study group was increased
(Silberstein et al., 1999). When the study population included
25% men, headache was relieved in 65%, whereas when the study
population had only 17% men, headache relief was reduced to
only 56% at 2 h post-administration (Lipton et al., 1998). In
a study of women alone, Excedrin ameliorated or eliminated
migraine in 58% of women at 2 h post dose (Silberstein et al.,
1999). Assuming that the efficacy in the study of women alone
is representative of the effectiveness of Excedrin, a simple
calculation based on the population with the highest percentage
of men in the Lipton et al. study can be used to estimate efficacy
in men. This calculation suggests that the efficacy of this therapy
in men would have been around 86% to produce the overall rate
reported in the combined studies. There is some evidence that
men are more likely to use ASA for migraine than women, and
this might be explained, in part, by an increased efficacy of ASA
in men, however, to date, no research has investigated if such a
difference exists.
CGRP receptor antagonists
The gepants, e.g., rimegepant, are small molecule CGRP receptor
antagonists, which have shown some promise as abortives in
migraine headache treatment (Croop et al., 2019). Antagonism at
this receptor attenuates neurogenic inflammation and is effective
in aborting migraine headache (Edvinsson et al., 2018). Evidence,
discussed below, suggests that CGRP receptor antagonists could
exhibit sex-related differences in their efficacy. In the most recent,
placebo controlled study, 85% of migraine patients enrolled were
women, and no assessment of sex-related differences in drug
efficacy was reported (Croop et al., 2019).
In healthy humans, plasma CGRP levels are higher in woman
than in men (Valdemarsson et al., 1990). There appears to be a
greater expression of the CGRP receptors by trigeminal ganglion
neurons in male than in female rats, but a higher baseline
expression of CGRP in the brainstem of female rats (Stucky et al.,
2011). Estrogen does not appear to alter the expression of CGRP
in some animal studies, but in others increased its expression
(Gupta et al., 2011; Aggarwal et al., 2012). Application of CGRP
to the dura of male and female rats resulted in lower facial
mechanical withdrawal thresholds in female rats for 72 h, but not
in male rats (Avona et al., 2019). Furthermore, dural application
of CGRP in female, but not male rats caused nociceptive priming,
which was evident up to 14 days post-administration (Avona
et al., 2019). Application of CGRP to the dura of male rats
does not excite or mechanically sensitize dural afferent fibers,
but does increase dural blood flow (Levy et al., 2005). Results
from experiments to examine the effect of CGRP on dural
afferent fiber response characteristics in female rats have not been
reported. However, while CGRP mediates increased blood flow,
it does not appear to contribute to the mechanical sensitization
of temporalis muscle nociceptors by intramuscular injection of
glutamate in female rats, which suggests that CGRP may not
directly affect trigeminal nociceptors in either sex (Gazerani et al.,
2010). Treatment of ovariectomized rats with estrogen raises
CGRP plasma levels and increases CGRP expression in arterioles
(Gupta et al., 2011). This is in line with findings that plasma levels
of CGRP are higher in women than in men, and increased by
estrogen containing birth control pills (Gupta et al., 2011).
Glutamate-receptor antagonists
Ketamine is an antagonist at nicotinic, muscarinic and the
N-methyl-D-aspartate (NMDA) glutamate receptor subtypes. It
is a centrally acting analgesic, although it may also exert some of
its antimigraine effects by inhibition of neurogenic inflammation,
as trigeminal afferent fibers express a subtype of the NMDA
receptor (Wang et al., 2012). It is not clear whether ketamine is
effective in migraine, although studies with intranasal ketamine
suggest that it may reduce headache-related pain (Afridi et al.,
2013; Etchison et al., 2018; Benish et al., 2019).
Trigeminal nociceptors in both animals and humans express
NR2B subunit containing NMDA receptors, with a greater
expression in females than in males (Wong et al., 2014). The
expression of peripheral NMDA receptors by nociceptors in the
trigeminal system is modulated by estrogenic tone and NMDA-
evoked afferent discharge is also greater in female rats (Dong
et al., 2007). In healthy human subjects, injection of glutamate
into the masseter muscle results in pain that can be attenuated
by co-administration of ketamine. A higher concentration of co-
administered ketamine is required to attenuate this muscle pain
in women, which is consistent with the greater expression of
NMDA receptors by masticatory muscle nociceptors in women
(Cairns et al., 2003; Castrillon et al., 2007, 2012). Theoretically,
ketamine might be more effective as an analgesic/abortive in men.
Opioids
Opioids are occasionally used as abortives and act on three
receptor subtypes to exert analgesic effects. These receptors
are found throughout the central nervous system and may be
expressed by a subgroup of trigeminal primary afferent fibers.
Activation of these receptors decreases neurotransmitter release
(pre-synaptic inhibition) and neuronal excitability (post-synaptic
inhibition). There is some evidence that morphine produces
greater analgesia in women and is more likely to be prescribed for
women with migraine (Niesters et al., 2010; Connelly et al., 2019).
Prophylactic Treatment of Migraine
Prophylactic agents are used to reduce the frequency of migraine
attacks and include beta-blockers, calcium channel blockers,
antidepressants, botulinum neurotoxin, and antibodies against
CGRP. Reports on sexually dimorphic responses to migraine
preventive therapy are lacking (Vetvik and Macgregor, 2017).
However, it has been found that women are more likely than men
to use prophylactic medication (Vetvik and Macgregor, 2017).
Levels of prophylactic use in both men and women are far lower
than the recommendations (Buse et al., 2013).
Among beta-blockers, propranolol plasma binding has been
found similar in both sexes, while its clearance is decreased
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in women (Soldin et al., 2011). Clearance of oral atenolol is
lower in women, which together with its lower volume of
distribution results in a higher systemic exposure of women
to this agent. Among calcium channel blockers, verapamil
clearance is more rapid in women following intravenous
administration, whereas after oral administration, clearance
is higher in men. The bioavailability of oral verapamil is
higher in women, which can lead to an increased systemic
exposure in women. Biotransformation of verapamil by CYP3A4
and p-glycoprotein (PGP) in liver and gut is different in
women and men and can lead to more complex differences
in clearance between the sexes (Soldin et al., 2011). Selective
serotonin reuptake inhibitors are another class of drugs that
are used as prophylactic agents in migraine and overall, due
to lower hepatic metabolism, plasma concentrations tend to
be higher in women (Soldin et al., 2011). Antibodies against
CGRP (e.g., galcanezumab) or its receptor (erenumab) have
been marketed recently for prophylactic therapy. It is not yet
clear if CGRP antibodies show different efficacy in women
and men. However, erenumab, when it was tested in a rat
model of IS, showed no sex-related difference in efficacy
(Stucky et al., 2011).
Potential Mechanisms of Sex-Related
Responses to Pharmacotherapy of
Migraine
There is limited information about underlying mechanisms of
sex-related differences in the pharmacotherapy of migraine. The
studies reviewed here suggest that both pharmacodynamic (PD)
and PK mechanisms may underlie sex-related differences in
response to migraine pharmacotherapy (Figure 1). Expression
of CGRP and its receptors appears to be different in males
and females, which may suggest PD-related mechanisms. In
this respect, it might be proposed that women would be better
responders to abortive and/or prophylactic therapy because there
is a stronger relationship between CGRP expression and migraine
headache in women. Sex-related differences in absorption,
distribution, metabolism, and excretion of therapeutic agents for
migraine may result in PK-related mechanisms. For example,
ingested oral ASA is more rapidly eliminated in women than
in men, which may explain an apparent greater analgesic
efficacy of ASA in men.
For future investigation in both preclinical and clinical
trials, it is recommended that the study design includes the
question of potential sex-related differences in therapeutic
response and their mechanism (Vetvik and Macgregor, 2017).
Another important aspect is the current lack of information
on sex-differences in the adverse effects of analgesic drugs in
the literature (Richardson and Holdcroft, 2009). For example,
unwanted effects following administration of opioid; including
nausea, vomiting, and respiratory depression occur more often
in women than in men (Fillingim et al., 2005). In this context,
sex-related differences in metabolism of certain analgesics,
such as acetaminophen and ASA, as well as contributions
from sex hormones, genetic variation, and co-administration
of drugs for comorbid conditions, such as depression, may
differentially affect adverse response to analgesics. It has also been
proposed that women have a greater awareness of medication
risks, which may be another factor that contributes to sex-
related differences in the occurrence of certain adverse effects
(Richardson and Holdcroft, 2009).
As has already been found in neuropathic pain, future
research should also clarify if non-neuronal cells, e.g., glia, play
FIGURE 1 | Pharmacodynamic and pharmacokinetic mechanisms that could, theoretically, differentially affect the disposition of drugs used for migraine therapy in
men and women. Specific examples include lower levels of ASA in women due to more rapid absorption and degradation, higher levels of propranolol, codeine, and
tramadol in women due to lower CYP activity, and lower levels of paracetamol in men due to more rapid glucuronidation. It remains unknown whether any of these
sex-related differences contribute to the effectiveness of these or other analgesic drugs when used for migraine treatment in men and women. ASA, acetylsalicylic
acid; CYP, cytochrome P450; CGRP, calcitonin gene-related peptide; GI, gastrointestinal; NMDA, N-methyl-D-aspartate.
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a role in sex-related differences in migraine and its treatment
(Machelska and Celik, 2016).
Since psychosocial factors, such as expectations, stereotypes,
cultural differences, pain-related beliefs, past experiences of
pain, and environmental stress can influence pain perception
(Packiasabapathy and Sadhasivam, 2018), it is highly valuable
to consider how these factors may influence sex-related
differences in response to migraine pharmacotherapy. Women
use a diverse range of pain coping strategies including social
support, emotion-focused techniques, attention focus, cognitive
re-interpretation, and positive self-statement (Unruh et al.,
1999; Packiasabapathy and Sadhasivam, 2018). On the other
hand, problem-focused techniques and behavioral distraction
are more common strategies used by men (Unruh et al.,
1999; Fillingim et al., 2009; Packiasabapathy and Sadhasivam,
2018). Catastrophizing with magnification and self-rumination
of pain is higher in women (Forsythe et al., 2011). Taken
together, these factors reinforce the value of recognition
and utilization of the biopsychosocial model (Engel, 1977;
Borrell-Carrio et al., 2004) in migraine research and
treatment. The influence of psychological interventions, such
as behavioral modifications, or pain coping strategies, on
response to migraine pharmacotherapy needs to be considered
in future studies.
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